Table 1.
Two-year evolution of immunogenicity and incidence of ZVL in cohorts of Leishmune®-vaccinated and untreated dogs
| Treatment | FMLELISA positive (%) |
Symptoms of ZVL/alive (%) |
DTH positive (%) |
ZVL confirmed deaths (%) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| D0 | D70 | D0 | M7 | M9 | M13-15 | m7 | m12 | M9 | M13-15 | M24 | |
| Leishmune® | 0 (0/550) | 98.0 (423/432) | 0 (0/550) | 0.4 (2/540) | 0.4 (2/536) | 0.4 (2/527) | 58.9 (129/219) | 82.7 (105/127) | 0.2 (1/537) | 0.4 (2/529) | 0.4 (2/523) |
| Untreated | 0 (0/581) | 15.6 (92/588) | 0 (0/580) | 5.4 (32/588) | 5.5 (25/455) | 9.7 (28/288) | ND | ND | 8.1 (37/455) | 3.6 (15/418) | 27.3 (42/154) |
| χ2 | p > 0.05 | p < 0.005 | p > 0.05 | p < 0.005 | p < 0.005 | p < 0.005 | p < 0.005 | p < 0.005 | p < 0.005 | ||
Data obtained from Leishmune®-vaccinated dogs of Araçatuba and Andradina, SP, and from untreated exposed dogs of Jardim Progresso RN, 2 years after vaccination. D, day; M, month; ND, not determined.